Skip to main content

Advertisement

Log in

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

We previously demonstrated that an angiotensin II receptor blocker (ARB) had the potential to inhibit cell proliferation of prostate cancer. In this study, we examined whether an ARB could elicit an antiproliferative effect on hormone-refractory prostate cancer, clinically.

Methods

Twenty-three patients with advanced hormone-refractory prostate cancer who had already received secondary hormonal therapy using dexamethasone, and who were no longer receiving conventional therapy, were enrolled. All of the patients received candesartan 8 mg once daily per os and, simultaneously, androgen ablation. Change in prostate-specific antigen (PSA) was determined as the primary endpoint. The secondary end-point was change in performance status (PS). To investigate angiotensin II type 1 (AT1) receptor expression in prostate cancer tissue, real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, using specimens, from untreated patients with prostate cancer.

Results

Eight patients (34.8%) showed responsive PSA changes; six showed a decrease immediately after starting administration and two showed a stable level of PSA. Six men with a PSA decline of more than 50% showed an improvement in PS. The mean time to PSA progression (TTPP) in responders was 8.3 months (range, 1–24 months). Half of the patients showed stable or improved PS during treatment. With regard to toxic effects, only one patient showed hypotension during treatment. The RT-PCR showed that AT1 receptor expression in well-differentiated adenocarcinoma was higher than that in poorly differentiated adenocarcinoma.

Conclusion

These data showed that an ARB had potential biological effects on prostate cancer, suggesting the usefulness of the cytostatic activity of such agents on recurrent prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A Jemal A Thomas T Murray et al. (2002) ArticleTitleCancer Statistics CA Cancer J Clin 52 23–47 Occurrence Handle11814064 Occurrence Handle10.3322/canjclin.52.1.23

    Article  PubMed  Google Scholar 

  2. InstitutionalAuthorNameThe Research Group for Population-Based Cancer Registration in Japan (2004) Cancer incidence in Japan K Tajima T Kuroishi A Oshima (Eds) Cancer mortality and morbidity statistics. Monograph on cancer research, No. 51 Japan Scientific Societies Press Karger, Tokyo 95–99

    Google Scholar 

  3. DP Petrylak CM Tangen MH Hussain et al. (2004) ArticleTitleDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513–1520 Occurrence Handle15470214 Occurrence Handle10.1056/NEJMoa041318 Occurrence Handle1:CAS:528:DC%2BD2cXot1Kmu7c%3D

    Article  PubMed  CAS  Google Scholar 

  4. G Liu K Oettel G Ripple et al. (2002) ArticleTitlePhase I trial of 1 alpha-hydroxyvitamin D (2) in patients with hormone refractory prostate cancer Clin Cancer Res 8 2820–2827 Occurrence Handle12231522 Occurrence Handle1:CAS:528:DC%2BD38XnvVWisLY%3D

    PubMed  CAS  Google Scholar 

  5. G Liu G Wilding MJ Staab et al. (2003) ArticleTitlePhase II study of 1 alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer Clin Cancer Res 9 4077–4083 Occurrence Handle14519629 Occurrence Handle1:CAS:528:DC%2BD3sXns1OjtL0%3D

    PubMed  CAS  Google Scholar 

  6. MA Carducci RJ Padley JV Breul et al. (2003) ArticleTitleEffect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial J Clin Oncol 21 679–689 Occurrence Handle12586806 Occurrence Handle10.1200/JCO.2003.04.176 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGrurY%3D

    Article  PubMed  CAS  Google Scholar 

  7. JB Nelson AA Nabulsi NJ Vogelzang et al. (2003) ArticleTitleSuppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan J Urol 169 1143–1149 Occurrence Handle12576870 Occurrence Handle1:CAS:528:DC%2BD3sXht1Cms7c%3D

    PubMed  CAS  Google Scholar 

  8. S Fujiyama H Matsubara Y Nozawa et al. (2001) ArticleTitleAngiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation Circ Res 88 22–29 Occurrence Handle11139469 Occurrence Handle1:CAS:528:DC%2BD3MXosVOjsw%3D%3D

    PubMed  CAS  Google Scholar 

  9. H Uemura H Ishiguro N Nakaigawa et al. (2003) ArticleTitleAngiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor Mol Cancer Ther 2 1139–1147 Occurrence Handle14617787 Occurrence Handle1:CAS:528:DC%2BD3sXovFCqtLk%3D

    PubMed  CAS  Google Scholar 

  10. GJ Bubley M Carducci W Dahut et al. (1999) ArticleTitleEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 3461–3467 Occurrence Handle10550143 Occurrence Handle1:STN:280:DC%2BD3c%2FhvValsg%3D%3D

    PubMed  CAS  Google Scholar 

  11. H Ishiguro N Nakaigawa Y Miyoshi et al. (2005) ArticleTitleReceptor for advanced glycation end products (RAGE) and its ligand, amphoterin, are overexpressed and associated with prostate cancer progression Prostate 64 92–100 Occurrence Handle15666359 Occurrence Handle10.1002/pros.20219 Occurrence Handle1:CAS:528:DC%2BD2MXls1ejur8%3D

    Article  PubMed  CAS  Google Scholar 

  12. H Hasumi H Ishiguro M Nakamura et al. (2005) ArticleTitleNeuroserpin (pi-12) is up-regulated in high-grade prostate cancer and is associated with survival Int J Cancer 115 911–916 Occurrence Handle15723353 Occurrence Handle10.1002/ijc.20967 Occurrence Handle1:CAS:528:DC%2BD2MXltlWrsL0%3D

    Article  PubMed  CAS  Google Scholar 

  13. AW Hahn U Jonas FR Buhler et al. (1994) ArticleTitleActivation of human peripheral monocytes by angiotensin II FEBS Lett 347 178–180 Occurrence Handle7518396 Occurrence Handle10.1016/0014-5793(94)00531-1 Occurrence Handle1:CAS:528:DyaK2cXltVSltLw%3D

    Article  PubMed  CAS  Google Scholar 

  14. EK Rice GH Tesch Z Cao et al. (2003) ArticleTitleInduction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II Kidney Int 63 1265–1275 Occurrence Handle12631343 Occurrence Handle10.1046/j.1523-1755.2003.00875.x Occurrence Handle1:CAS:528:DC%2BD3sXjtVymtrc%3D

    Article  PubMed  CAS  Google Scholar 

  15. H Sato A Watanabe T Tanaka et al. (2003) ArticleTitleRegulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors J Mol Cell Cardiol 35 1197–1205 Occurrence Handle14519430 Occurrence Handle10.1016/S0022-2828(03)00210-4 Occurrence Handle1:CAS:528:DC%2BD3sXns1Krurw%3D

    Article  PubMed  CAS  Google Scholar 

  16. B Amann R Tinzmann B Angelkort (2003) ArticleTitleACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 Diabetes Care 26 2421–2425 Occurrence Handle12882873 Occurrence Handle1:CAS:528:DC%2BD3sXmslOkuro%3D

    PubMed  CAS  Google Scholar 

  17. DW Moskowitz FE Johnson (2004) ArticleTitleThe central role of angiotensin-converting enzyme in vertebrate pathophysiology Curr Top Med Chem 4 1433–1454 Occurrence Handle15379656 Occurrence Handle10.2174/1568026043387818 Occurrence Handle1:CAS:528:DC%2BD2cXnslCms7Y%3D

    Article  PubMed  CAS  Google Scholar 

  18. AF Lever DJ Hole CR Gillis et al. (1998) ArticleTitleDo inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 179–184 Occurrence Handle9683206 Occurrence Handle10.1016/S0140-6736(98)03228-0 Occurrence Handle1:CAS:528:DyaK1cXlt1altbs%3D

    Article  PubMed  CAS  Google Scholar 

  19. ME Ullian LG Walsh TA Morinelli (1996) ArticleTitlePotentiation of angiotensin II action by corticosteroids in vascular tissue Cardiovasc Res 32 266–273 Occurrence Handle8796113 Occurrence Handle10.1016/0008-6363(96)00053-3 Occurrence Handle1:CAS:528:DyaK28XlsVahu7o%3D

    Article  PubMed  CAS  Google Scholar 

  20. DF Guo S Uno T Inagami (1995) ArticleTitleSteroid hormones upregulate rat angiotensin II type 1A receptor gene: role of glucocorticoid responsive elements in rat angiotensin II type 1A promoter J Steroid Biochem Mol Biol 53 69–73 Occurrence Handle7626519 Occurrence Handle10.1016/0960-0760(95)00023-S Occurrence Handle1:CAS:528:DyaK2MXnt1Gns7c%3D

    Article  PubMed  CAS  Google Scholar 

  21. M Sano K Fukuda T Sato et al. (2001) ArticleTitleERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts Circ Res 89 661–669 Occurrence Handle11597988 Occurrence Handle1:CAS:528:DC%2BD3MXnsF2kt70%3D

    PubMed  CAS  Google Scholar 

  22. CJ Logothetis KK Wu LD Finn et al. (2001) ArticleTitlePhase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin Cancer Res 7 1198–1203 Occurrence Handle11350884 Occurrence Handle1:CAS:528:DC%2BD3MXktlemu7o%3D

    PubMed  CAS  Google Scholar 

  23. K Egami T Murohara T Shimada et al. (2003) ArticleTitleRole of host angiotensin II type 1 receptor in tumor angiogenesis and growth J Clin Invest 112 67–75 Occurrence Handle12840060 Occurrence Handle10.1172/JCI200316645 Occurrence Handle1:CAS:528:DC%2BD3sXlt1Krt7g%3D

    Article  PubMed  CAS  Google Scholar 

  24. D Ingber T Fujita S Kishimoto et al. (1990) ArticleTitleSynthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 348 555–557 Occurrence Handle1701033 Occurrence Handle10.1038/348555a0 Occurrence Handle1:CAS:528:DyaK3MXpsVOntw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  25. M Yamaoka T Yamamoto T Masaki et al. (1993) ArticleTitleInhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) Cancer Res 53 4262–4267 Occurrence Handle7689930 Occurrence Handle1:CAS:528:DyaK3sXmsVWjtro%3D

    PubMed  CAS  Google Scholar 

  26. MC Hall P Troncoso A Pollack et al. (1994) ArticleTitleSignificance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy Urology 44 869–875 Occurrence Handle7527168 Occurrence Handle1:STN:280:ByqD2snmtVQ%3D

    PubMed  CAS  Google Scholar 

  27. WD Figg W Dahut P Duray et al. (2001) ArticleTitleA randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 1888–1893 Occurrence Handle11448901 Occurrence Handle1:CAS:528:DC%2BD3MXlslaltbs%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroji Uemura.

About this article

Cite this article

Uemura, H., Hasumi, H., Kawahara, T. et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10, 405–410 (2005). https://doi.org/10.1007/s10147-005-0520-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-005-0520-y

Key words

Navigation